Health

Results: 3625-3636 of 4023

Luoxin Pharmaceutical's LX-039 (Innovative Anti-Tumor Drug): Phase I Clinical Study Data Presented at ESMO 2023

PR Newswire associated0

Mindray Expands Its Cardiac Biomarker Portfolio with Cutting-Edge hs-cTnI and NT-proBNP Assays, Empowering Enhanced Cardiovascular Diseases Care

Dom Marchant, Chief Creative Officer, joins the executive leadership team at OPEN Health with a new vision to drive the creative communications practice

First results from PEGASUS trial reported at ESMO show promise for use of liquid biopsy to guide adjuvant treatment of colon cancer

Genialis and Cancer Research Horizons Collaborate to Develop AI-Driven Patient Classifiers

BIMA MILVIK announces acquisition by CapitalSG and successful restructuring

Michigan Medicine harnesses the power of Sectra's digital pathology solution to enhance patient care and foster collaboration among physicians

PR Newswire associated0

Hummingbird Bioscience Announces Positive Phase I Clinical Data for HMBD-001 Monotherapy Trial at the European Society for Medical Oncology Congress 2023

Zymfentra® (Photo: Celltrion)

Celltrion, Inc. & Celltrion Healthcare Co., Ltd. Announce Shareholders Approval of Merger

ENHERTU® Approved in the EU as the First HER2 Directed Therapy for Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer

New Data on BerGenBio's Selective AXL Inhibitor Bemcentinib Released Today at 2023 ESMO Meeting

Nanoform grant Global STARMAP® AI License to AstraZeneca